Fig. 6
From: A kinase-independent role for CDK8 in BCR-ABL1+ leukemia
CDK8 regulates the mTOR pathway. a Gene set enrichment analysis (RNA-seq data) reveals 14 significantly downregulated pathways in BCR-ABL1p185+ Cdk8Δ/ΔVav-Cre cells. NES: normalized enrichment score. b Immunoblots of five independent cell lines per genotype were probed for pAKTS473, total AKT, pS6S240/244, total S6, p4E-BPT34/46, and total 4E-BP-1. In addition, pSTAT5S725, STAT5, and CDK8 were blotted. β-Actin served as loading control. c Bar diagrams depict densitometric analysis of signal intensities relative to the loading control (of western blottings shown in b). d Representative dose–response curves for Torin1, Everolimus, BEZ235, and Cal101; mean ± SD. Table includes IC50 values of Torin1 (mTORC1 and mTORC2), Everolimus (mTORC1), BEZ235 (PI3K/ATM/ATR and mTOR), Cal101 (PI3Kdelta), Bay11 (NFκB), Ruxolitinib (JAK1 and JAK2), PDK1/Akt and Flt3/Pim dual inhibitor, THZ-1 (CDK7) and NVP-2 (CDK9) on BCR-ABL1p185+ Cdk8fl/fl, and BCR-ABL1p185+ Cdk8Δ/ΔVav-Cre cell lines. Data represent the summary of one to three cell lines per genotype in technical triplicates. Asterisks denote statistical significances as determined by an unpaired t-test; mean ± SD (*p < 0.05; **p < 0.01). Source data are provided as a Source Data file
